| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer F Di Nicolantonio, M Martini, F Molinari, A Sartore Bianchi, S Arena, ... Journal of clinical oncology 26 (35), 5705-5712, 2008 | 2093 | 2008 |
| Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ... Jama 304 (16), 1812-1820, 2010 | 847 | 2010 |
| Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus F Di Nicolantonio, S Arena, J Tabernero, S Grosso, F Molinari, ... The Journal of clinical investigation 120 (8), 2858-2866, 2010 | 380 | 2010 |
| Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ... Science translational medicine 6 (224), 224ra26-224ra26, 2014 | 269 | 2014 |
| Adaptive mutability of colorectal cancers in response to targeted therapies M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ... Science 366 (6472), 1473-1480, 2019 | 261 | 2019 |
| Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal CancerEGFR Mutations and Resistance to Cetuximab S Arena, B Bellosillo, G Siravegna, A Martínez, I Cañadas, L Lazzari, ... Clinical cancer research 21 (9), 2157-2166, 2015 | 258 | 2015 |
| EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal CancerOvercoming KRASG12C Inhibitor Resistance in Colorectal Cancer V Amodio, R Yaeger, P Arcella, C Cancelliere, S Lamba, A Lorenzato, ... Cancer discovery 10 (8), 1129-1139, 2020 | 200 | 2020 |
| Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells H Konishi, M Mohseni, A Tamaki, JP Garay, S Croessmann, S Karnan, ... Proceedings of the National Academy of Sciences 108 (43), 17773-17778, 2011 | 191 | 2011 |
| Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer BO Van Emburgh, S Arena, G Siravegna, L Lazzari, G Crisafulli, G Corti, ... Nature communications 7 (1), 13665, 2016 | 180 | 2016 |
| Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET C Basilico, S Pennacchietti, E Vigna, C Chiriaco, S Arena, A Bardelli, ... Clinical Cancer Research 19 (9), 2381-2392, 2013 | 165 | 2013 |
| High-dose vitamin C enhances cancer immunotherapy A Magrì, G Germano, A Lorenzato, S Lamba, R Chilà, M Montone, ... Science Translational Medicine 12 (532), eaay8707, 2020 | 132 | 2020 |
| Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses F Di Nicolantonio, S Arena, M Gallicchio, D Zecchin, M Martini, SE Flonta, ... Proceedings of the National Academy of Sciences 105 (52), 20864-20869, 2008 | 114 | 2008 |
| Genetic analysis of the kinome and phosphatome in cancer S Arena, S Benvenuti, A Bardelli Cellular and Molecular Life Sciences CMLS 62, 2092-2099, 2005 | 109 | 2005 |
| PIK3CA cancer mutations display gender and tissue specificity patterns S Benvenuti, M Frattini, S Arena, C Zanon, V Cappelletti, D Coradini, ... Human mutation 29 (2), 284-288, 2008 | 103 | 2008 |
| Expression and functional regulation of myoglobin in epithelial cancers SE Flonta, S Arena, A Pisacane, P Michieli, A Bardelli The American journal of pathology 175 (1), 201-206, 2009 | 96 | 2009 |
| Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal CancerResistance to BRAF Combination Therapies in Colon Cancer D Oddo, EM Sennott, L Barault, E Valtorta, S Arena, A Cassingena, ... Cancer research 76 (15), 4504-4515, 2016 | 95 | 2016 |
| MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations S Arena, G Siravegna, B Mussolin, JD Kearns, BB Wolf, S Misale, ... Science translational medicine 8 (324), 324ra14-324ra14, 2016 | 90 | 2016 |
| A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and OxaliplatinOlaparib and Oxaliplatin Cross-Sensitivity in Colorectal Cancer S Arena, G Corti, E Durinikova, M Montone, NM Reilly, M Russo, ... Clinical Cancer Research 26 (6), 1372-1384, 2020 | 67 | 2020 |
| The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal CancerSym004 Overcomes EGFR … FJ Sánchez-Martín, B Bellosillo, M Gelabert-Baldrich, A Dalmases, ... Clinical Cancer Research 22 (13), 3260-3267, 2016 | 66 | 2016 |
| p21 (WAF1/CIP1) Mediates the Growth Response to TGF-b in Human Epithelial Cells KE Bachman, BG Blair, K Brenner, A Bardelli, S Arena, S Zhou, J Hicks, ... Cancer biology & therapy 3 (2), 221-225, 2004 | 62 | 2004 |
